NCT05186545 2022-09-02An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerThe First Affiliated Hospital of Zhengzhou UniversityPhase 2 Unknown63 enrolled